New Drug Applications

FDA Issues Complete Response Letter for Etripamil for PSVT

1 year ago
by David Miller
961 Views
Written by David Miller

MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts
[mwai_chat window="true" fullscreen="true"]